×

Intention & Expectations

By Stacie Prada Lately, I’ve been pausing periodically throughout each day to ask myself, “How do I want to show up today?” It only takes a moment, just enough time for a brief inhale and exhale. It allows me to … Continue reading → Source:…

Remyelination in Monkeys with Clemastine

Tweet In the UK people have a real issue with non-human primate research and there is essentially no MS related work ongoing in the UK. You know we love our furry friends and in the 1980s when I worked in a place where people worked…

UCSF, Nektar team to test potential of antibody therapy for MS

The University of California San Francisco (UCSF) is teaming up with Nektar Therapeutics to study the potential of NKTR-0165, an experimental antibody that activates the tumor necrosis factor receptor type 2 (TNFR2), to treat multiple sclerosis (MS). UCSF neurologist Stephen L. Hauser, MD, and his…

Alguns dels nostres protagonistes d’«I a tu, què t’ha robat l’EM?» assisteixen al recital de Joshua Bell al Palau de la Música Catalana

Gràcies a la generositat de Teaming, la plataforma de micromecenatge més gran d’Espanya, hem pogut oferir 7 entrades gratuïtes en una llotja del Palau de la Música Catalana per assistir al concert de la Franz Schubert Filharmonia, celebrat el dimecres 11 de febrer a les…

Cost of Drugs

Tweet Hartung DM et al. Changes in List and Net Prices for Multiple Sclerosis Disease-Modifying Therapy, 2013 to 202116  e200597 Neurol Clin Practise 2026 https://doi.org/10.1212/CPJ.00000000002005 This is a paper that tweaked my interest and says to the people in the UK to spare a thought for…

Subtle voice changes may help doctors identify multiple sclerosis faster

Canary Speech and Intermountain Ventures are collaborating to test whether subtle changes in a person’s voice can help identify multiple sclerosis (MS), potentially paving the way for noninvasive tools to diagnose the disease faster. The research will rely on Canary’s vocal biomarker technology and be led…

Funding to support Immunic Phase 3 MS trials, commercialization

Immunic Therapeutics has closed a private placement that could provide up to $400 million to support the company’s Phase 3 clinical program of vidofludimus calcium in multiple sclerosis (MS) and help fund its transition into a commercial-stage company as it prepares for potential regulatory approval…